Measurments Of BBB Breakdown In The Pathogenesis Of Psychiatric Disorders

Status Not yet recruiting

Clinical Trial Summary

BBB dysfunction has been indicated in some groups of schizophrenia patients by measuring increased albumin and immunoglobulin (IgG) cerebrospinal fluid (CSF) levels. Most of the authors described a raised protein level in 5-20% of the schizophrenic patients (Muller & Ackenheil, 1995). Increased S100B levels were demonstrated in the serum of patients suffering from schizophrenia as well as depression, and this may reflect increased BBB permeability. Furthermore, this increase remains in those patients who develop a residual state with relevant negative symptoms, whereas S100B levels normalize in recovering patients (Shalev, Serlin & Friedman, 2009). CSF albumin and CSF IgG values correlate significantly with some of the SANS (Scale for the Assessment of Negative Symptoms) subscales and the SANS total score, this shows the correlation between BBB permeability and behavioral changes. It is important to say that although negative symptoms are often signs of chronicity of the disease, the abnormal CSF findings in Muller's experiment (1995) are not related to the duration of the disease, because the patients were quite young and the duration of the disease was less than 3 years.

The investigators hypothesize that a primary vascular pathology, which leads to BBB breakdown, will result a leakage of serum-derived vascular components in to the brain tissue and may cause brain dysfunction such as disturbed thinking processes, mood and behavior, as we can see in psychiatric patients.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01396850
Study type	Observational
Source	Soroka University Medical Center
Contact
Status	Not yet recruiting
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04929938` - Application of UP for Transdiagnostic Treatment of Emotional Disorders for UHR for Psychosis Patients	N/A
Recruiting	`NCT05863572` - Strengthening Care in Collaboration With People With Lived Experience of Psychosis in Uganda	N/A
Completed	`NCT04277585` - Improving Access to Early Psychosis Coordinated Specialty Care	N/A
Recruiting	`NCT06197048` - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder	N/A
Completed	`NCT04284813` - Families With Substance Use and Psychosis: A Pilot Study	N/A
Terminated	`NCT04404712` - FAAH Availability in Psychiatric Disorders: A PET Study	Early Phase 1
Recruiting	`NCT05769933` - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Recruiting	`NCT04298450` - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention	N/A
Not yet recruiting	`NCT05558332` - Youth Nominated Support Team	N/A
Not yet recruiting	`NCT05358457` - Pilot Study to Evaluate the Effectiveness of Online Familiar Metacognitive Training (MCTf)	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Completed	`NCT02895269` - COllaborative Shared Care to IMprove Psychosis Outcome	N/A
Recruiting	`NCT02622048` - Understanding and Helping Families: Parents With Psychosis	N/A
Completed	`NCT02531243` - Computer-Aided Learning for Managing Stress	N/A
Completed	`NCT02733575` - Compassion Focused Therapy for Distressing Experiences	N/A
Completed	`NCT02653729` - Cbt for Psychosis and Affect on Psychosis Symptoms	Phase 2
Not yet recruiting	`NCT02244970` - Mindfulness RCT for Early Psychosis	N/A
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Withdrawn	`NCT00786318` - Ziprasidone vs Standard Therapy for Agitated Patients in the ED	Phase 4
Recruiting	`NCT00722163` - A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis	Phase 0